DK2408912T3 - FOXM1 PEPTIDES AND VACCINES CONTAINING THESE - Google Patents

FOXM1 PEPTIDES AND VACCINES CONTAINING THESE Download PDF

Info

Publication number
DK2408912T3
DK2408912T3 DK10743558.8T DK10743558T DK2408912T3 DK 2408912 T3 DK2408912 T3 DK 2408912T3 DK 10743558 T DK10743558 T DK 10743558T DK 2408912 T3 DK2408912 T3 DK 2408912T3
Authority
DK
Denmark
Prior art keywords
cancer
peptide
foxm1
present
peptides
Prior art date
Application number
DK10743558.8T
Other languages
Danish (da)
English (en)
Inventor
Sachiko Yoshimura
Tomohisa Watanabe
Takuya Tsunoda
Ryuji Ohsawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DK2408912T3 publication Critical patent/DK2408912T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4242Transcription factors, e.g. SOX or c-MYC
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK10743558.8T 2009-02-18 2010-02-17 FOXM1 PEPTIDES AND VACCINES CONTAINING THESE DK2408912T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15340809P 2009-02-18 2009-02-18
PCT/JP2010/001005 WO2010095428A1 (en) 2009-02-18 2010-02-17 Foxm1 peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
DK2408912T3 true DK2408912T3 (en) 2017-03-20

Family

ID=42633716

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10743558.8T DK2408912T3 (en) 2009-02-18 2010-02-17 FOXM1 PEPTIDES AND VACCINES CONTAINING THESE

Country Status (15)

Country Link
US (1) US8617562B2 (enExample)
EP (1) EP2408912B1 (enExample)
JP (1) JP5728717B2 (enExample)
KR (1) KR101713586B1 (enExample)
CN (1) CN102405285B (enExample)
BR (1) BRPI1008887A2 (enExample)
CA (1) CA2752560C (enExample)
DK (1) DK2408912T3 (enExample)
ES (1) ES2618896T3 (enExample)
IL (1) IL214435A0 (enExample)
MX (1) MX2011008763A (enExample)
RU (1) RU2560431C2 (enExample)
SG (1) SG173751A1 (enExample)
TW (1) TWI469791B (enExample)
WO (1) WO2010095428A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117584B (zh) 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
GB201410686D0 (en) * 2014-06-16 2014-07-30 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3360886B1 (en) * 2015-10-08 2023-01-25 Oncotherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
CN105524159B (zh) * 2015-11-16 2021-04-09 西南交通大学 具有癌细胞选择性杀伤和迁移抑制作用的多肽分子与用途
CN105999227B (zh) * 2016-08-12 2019-08-06 湖南大学 FOXM1蛋白氮端(1-234 aa)的表达及其用途
JP2020503840A (ja) 2016-10-07 2020-02-06 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Hla拘束性vgll1ペプチドおよびその使用
CN111787930B (zh) * 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
HRP20230007T1 (hr) * 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
CN109055327B (zh) * 2018-07-23 2021-04-06 浙江工业大学 醛酮还原酶突变体及其应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN114591400B (zh) * 2022-03-29 2022-10-21 西南交通大学 一组靶向FoxM1-DBD多肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
EP0846761A1 (en) * 1996-12-09 1998-06-10 Introgene B.V. A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
ES2294844T3 (es) 1998-06-25 2008-04-01 Green Peptide Co., Ltd. Peptidos antigenicos tumorales derivados de ciclofilina b.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2448881A1 (en) 2001-06-04 2002-12-12 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants ii
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2469274A1 (en) 2001-12-10 2003-06-19 Kyogo Itoh Tumor antigens
US20040109844A1 (en) * 2002-08-28 2004-06-10 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
WO2005090991A1 (en) 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004031411A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
WO2005076979A2 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
JP4938451B2 (ja) 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 非小細胞肺癌の診断のための方法
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006141208A (ja) 2004-11-16 2006-06-08 Univ Of Tokushima 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤
EP2295601A1 (en) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
EP2018440A1 (en) 2006-04-20 2009-01-28 Oncotherapy Science, Inc. NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER
CN108117584B (zh) * 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
MX2010002001A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.
BRPI1009301A2 (pt) 2009-03-18 2016-03-08 Oncotherapy Science Inc peptídeos neil 3 e vacinas incluindo os mesmos

Also Published As

Publication number Publication date
EP2408912A4 (en) 2013-04-17
MX2011008763A (es) 2011-09-09
TW201032821A (en) 2010-09-16
KR20110117241A (ko) 2011-10-26
ES2618896T3 (es) 2017-06-22
RU2560431C2 (ru) 2015-08-20
WO2010095428A1 (en) 2010-08-26
US20120156231A1 (en) 2012-06-21
CN102405285A (zh) 2012-04-04
CA2752560A1 (en) 2010-08-26
RU2011138160A (ru) 2013-03-27
EP2408912B1 (en) 2017-01-18
KR101713586B1 (ko) 2017-03-08
CA2752560C (en) 2017-01-24
BRPI1008887A2 (pt) 2016-03-01
JP5728717B2 (ja) 2015-06-03
IL214435A0 (en) 2011-09-27
AU2010216980A1 (en) 2011-08-25
EP2408912A1 (en) 2012-01-25
TWI469791B (zh) 2015-01-21
JP2012517799A (ja) 2012-08-09
SG173751A1 (en) 2011-09-29
US8617562B2 (en) 2013-12-31
CN102405285B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
DK2408912T3 (en) FOXM1 PEPTIDES AND VACCINES CONTAINING THESE
US20140199335A1 (en) C1orf59 peptides and vaccines including the same
US9745343B2 (en) Method of inducing an immune response by administering WDRPUH epitope peptides
WO2010070877A1 (en) Elovl7 epitope peptides and vaccines containing the same
AU2010216980B2 (en) FOXM1 peptides and vaccines containing the same
HK1240953A1 (en) Wdrpuh epitope peptides and vaccines containing the same
HK1165460A (en) Foxm1 peptides and vaccines containing the same
HK1165460B (en) Foxm1 peptides and vaccines containing the same